Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DVR (3.24) Cal Dive Awarded 2nd Pemex Contract for 2012
Last update: 3/5/2012 7:30:01 AMHOUSTON, Mar 05, 2012 (BUSINESS WIRE) --
Cal Dive International, Inc. (DVR) announced today that it has been awarded a contract by Pemex Exploracion y Produccion for the installation of a 20 inch subsea pipeline located in the Abkatun Pol Chuc Field in 73 meters of water. The contract is expected to generate total revenue of approximately $46 million and will utilize two of the Company's key assets. The offshore construction is expected to commence in the second quarter 2012. Quinn Hebert, President and Chief Executive Officer of Cal Dive, stated, "We are pleased to announce our second contract win in Mexico for 2012. Mexico is shaping up to be a very active market in 2012 as expected. So far we have been awarded contracts in Mexico with aggregate expected revenue in 2012 of approximately $70 million compared to revenues generated from Mexico projects in 2011 of approximately $30 million."
Cal Dive International, Inc., headquartered in Houston, Texas, is a marine contractor that provides an integrated offshore construction solution to its customers, including manned diving, pipelay and pipe burial, platform installation and platform salvage services to the offshore oil and natural gas industry on the Gulf of Mexico OCS, Northeastern U.S., Latin America, Southeast Asia, China, Australia, the Middle East and the Mediterranean, with a fleet of 29 vessels, including 19 surface and saturation diving support vessels and 10 construction barges. SOURCE: Cal Dive International, Inc.
Cal Dive International, Inc. Brent Smith, (713) 361-2634 Executive Vice President, Chief Financial Officer and TreasurerCopyright Business Wire 2012
Looking for a profitable day trading. Staying positive.
From Reuters - "Rio Tinto To Invest $ Bin In India Iron Ore Project" - link on IGC board.
Nails: I cannot private message, but yes, I saw that and thanks anyway.
Ray
IGC the charts are perfectly set
ECRI Sticks to Recession Call, Even Amid Positive Signs
http://www.cnbc.com/id/46513890
IGC buying before China delivery news
LOCM watch this one IGC ALTI BPAX
good morning
ASTI trigger is 200sma imo
cool, that's great news for ECYT. ty.
ASTI- Sorry buddy but I've never played or followed that one before. I think i know a couple people on the GF board that are playing this one, I'll ask around today for ASTI DD
Good Morning AF, thank for the charts
SVNT Charts Current Share Price: $2.00 (Mar 3)
Good Morning ESVA
SVNT- Savient Announces Named Patient Programme for KRYSTEXXA® in the European Union for Patients with Refractory Chronic Gout
EAST BRUNSWICK, N.J., March 5, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that KRYSTEXXA®(pegloticase) is now available in the European Union to healthcare professionals and their patients suffering from refractory chronic gout (RCG) through a Named Patient Programme, which is sponsored by its wholly-owned subsidiary, Savient Pharma Ireland Limited, and managed by Idis Limited (Idis). RCG is a difficult-to-treat form of gout and currently there are no other available therapies approved in the European Union for the treatment of RCG. KRYSTEXXA is currently available in the U.S. and is the only U.S. Food and Drug Administration approved treatment for RCG.
"In responding to prescriber and patient requests for access to KRYSTEXXA in the European Union, we are pleased to have established this Named Patient Programme in collaboration with Idis as we continue to advance our efforts to ensure that patients suffering from RCG have access to KRYSTEXXA. We believe that KRYSTEXXA can address a significant unmet medical need globally and we remain committed to provide this therapy to those patients who suffer from this crippling, debilitating disease and have no other treatment options available to them," said Kenneth Bahrt, M.D., Senior Vice President and Chief Medical Officer of Savient Pharmaceuticals, Inc.
"We are pleased to be working with Savient to ensure that those patients with RCG have access to KRYSTEXXA through this Named Patient Programme," said Natalie Douglas, Chief Executive Officer, Idis. "We remain deeply committed to working in partnership with companies like Savient to give physicians and their patients access to new and innovative medicines through fully compliant channels."
Idis develops and implements Managed Access Programmes that allow patients with unmet medical needs to access medicines that are not available through the traditional clinical trial or commercial framework. For this programme, Idis will facilitate access to KRYSTEXXA on a named patient basis to European hospitals, pharmacies, physicians on behalf of their patients. Under a Named Patient Programme, treatments that are pending approval by the European Medicines Agency (EMA) can be legally administered to patients who are suffering from serious diseases until they are commercially available in each market. Savient is seeking approval for KRYSTEXXA in Europe and filed its regulatory application with the EMA in May 2011.
Healthcare professionals licensed in the European Union treating patients with RCG interested in KRYSTEXXA should contact Idis at:
Telephone: +44 (0) 1932824123 Fax: +44 (0) 1932824323
Email to: global@idispharma.com
ABOUT KRYSTEXXA®
KRYSTEXXA®(pegloticase) is a PEGylated uric acid specific enzyme for administration by intravenous infusion for the treatment of refractory chronic gout (RCG) in adult patients. KRYSTEXXA became commercially available in the U.S. by prescription on December 1, 2010 and is the only U.S. Food and Drug Administration approved product specifically indicated for the treatment of RCG. KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.
For more information about KRYSTEXXA, please visit: http://www.KRYSTEXXA.com.
IMPORTANT SAFETY INFORMATION ABOUT TREATMENT WITH KRYSTEXXA®
KRYSTEXXA is not indicated for the treatment of asymptomatic hyperuricemia. Patients who are at risk of having a condition known as G6PD deficiency should be screened by their physician prior to starting therapy with KRYSTEXXA.
Discontinue oral urate-lowering therapies before instituting KRYSTEXXA and do not institute oral urate-lowering therapy while the patient is on KRYSTEXXA therapy.
Possible side effects of KRYSTEXXA include:
Anaphylaxis which occurred in some patients treated with KRYSTEXXA. KRYSTEXXA should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis. Patients should be pre-medicated with antihistamines and corticosteroids. Patients should be closely monitored for an appropriate period of time for anaphylaxis after administration of KRYSTEXXA.
Infusion reactions which occurred in some patients treated with KRYSTEXXA. The risk of an infusion reaction is higher in patients who have lost therapeutic response. Because the risk of infusion reactions is higher in patients who lose therapeutic response to KRYSTEXXA, monitor serum uric acid before each infusion and consider discontinuing treatment if levels rise above 6mg/dL, particularly when two consecutive levels above 6 mg/dL are observed.
As with other urate-lowering therapies, an increase in gout flares was seen in some patients treated with KRYSTEXXA. Gout flare prophylaxis with a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended starting at least 1 week before initiation of KRYSTEXXA therapy and lasting at least 6 months, unless medically contraindicated or not tolerated.
KRYSTEXXA has not been formally studied in patients with congestive heart failure, but some patients in clinical trials experienced exacerbation. Exercise caution when using KRYSTEXXA in patients who have congestive heart failure and monitor patients closely following infusion. Patients receiving re-treatment may be at increased risk for anaphylaxis and infusion reactions and should be monitored carefully.
ADVERSE REACTIONS
The most commonly reported serious adverse reactions are anaphylaxis, infusion reactions and gout flares. Most common adverse reactions: gout flares (77%), infusion reactions (26%), nausea (12%), contusion or ecchymosis (11%), nasopharyngitis (7%), constipation (6%), chest pain (6%), anaphylaxis (5%), and vomiting (5%).
Please see the Full Prescribing Information and Medication Guide at http://www.KRYSTEXXA.com.
ABOUT REFRACTORY CHRONIC GOUT
Gout is a painful, debilitating form of arthritis and affects approximately eight million people in the U.S. alone. A significant sub-population of gout patients, approximately 120,000, are burdened with a difficult-to-treat form of the condition known as refractory chronic gout (RCG). Symptoms of gout are caused by the body's response to the presence of uric acid crystals in the joints and surrounding tissue which form when uric acid levels in the blood are elevated (a condition called hyperuricemia). The longer hyperuricemia persists, the higher the risk of developing gout. Symptoms of gout may include painful flares, pain or swelling in the joints (known as "gouty arthritis") or deposits of uric acid crystals under the skin, called "tophi." In cases of RCG, these symptoms may have a major influence on patient health-related quality of life due to the frequency and severity of episodes, the recurrent pain and the disfigurement associated with this condition. Although most cases of gout can be controlled with conventional urate-lowering therapy, when uric acid levels remain high and symptoms persist despite treatment efforts, chronic gout may be defined as refractory.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA®(pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin®(oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.
ABOUT Idis
Around the world, patients with unmet medical needs are frequently driven to seek access to medicines outside the clinical trial and commercial setting. Idis is the leading expert in developing, implementing and managing global Managed Access Programs by which pharmaceutical and biotechnology companies and healthcare providers can respond to the needs of these patients. "Managed Access" is an umbrella term encompassing a variety of different regulatory approaches, including Named Patient Programs that enable access to medicines that are not available to patients via the traditional clinical or commercial route.
Idis has 25 years experience of partnering with pharmaceutical and biotechnology companies to create regulatory-compliant, ethical access to medicines for healthcare professionals and their patients with unmet medical needs.
Since 1987, Idis has developed and managed access to thousands of medicines from virtually every therapeutic category, impacting the lives of hundreds of thousands of patients in countries around the world. For more information please visit: www.idispharma.com.
MPG Office Trust, Inc. to Release Fourth Quarter 2011 Financial Results on March 5, 2012
Stocks set to open lower today...
U.S. stocks were set to open lower Monday, following the path of world markets, after China lowered its annual growth target.
Investors also are bracing for a week full of news on Greece's rescue package and the domestic labor market.
The Dow Jones industrial average (INDU), S&P 500 (SPX) and Nasdaq (COMP) futures were all about 0.4% lower. Stock futures indicate the possible direction of the markets when they open at 9:30 a.m. ET.
World markets were in the red Monday, after Chinese Premier Wen Jiabao set a lower target for China's economic growth, underscoring the need to make the country's breakneck development more sustainable.
The government is aiming for economic growth of 7.5% in 2012, Wen said -- lower than the 2011 goal of about 8%. The Chinese economy often exceeds the official objective: last year it grew 9.2%.
On the domestic front, investors will head into the week looking for more evidence of a U.S. recovery under way, while keeping tabs on developments on Europe's debt crisis.
"The Chinese downgrading their economic target is sending a little bit of a jitter through European markets," said David Jones, chief market strategist at IG Index.
"But in general, we've seen fairly quiet markets over the last few weeks, and that might continue until we get the payroll data out of the way on Friday," he said.
European leaders inked a pact on Friday aimed at ensuring fiscal discipline across the continent. However, they have yet to make a decision on the size of the "financial firewall" that many believe is necessary if countries such as France and Spain face further distress.
Stocks closed modestly lower Friday, with the Dow snapping a three-week winning streak.
World markets: European stocks retreated in midday trading. Britain's FTSE 100 (UKX) lost 0.5%, the DAX (DAX) in Germany dropped 1.2% and France's CAC 40 (CAC40) shed 0.8%.
Asian markets ended lower. The Shanghai Composite (SHCOMP) closed down 0.6%, while the Hang Seng (HSI) in Hong Kong lost 1.4% and Japan's Nikkei (N225) dropped 0.8%.
Gas prices hit $3.77 a gallon
Economy: Reports are due Monday morning on the services sector and factory orders.
Last week, the ISM manufacturing index for February slipped to 52.4, from 54.1 in January, indicating a slowdown in the sector's expansion. The February edition of the ISM services index is expected to come in at 56, down from 56.8 in the month prior, which would also signal a slower expansion.
January factory orders are expected to have decreased by 1.9%, according to a survey of analysts by Briefing.com, after ticking up by 1.1% in December.
Coming later in the week are data on consumer credit and the monthly jobs report.
Companies: Online reviews site Yelp (YELP) will look to continue its momentum Monday, after shares spiked 64% to top $24 a share in their debut on the New York Stock Exchange Friday.
BP shares were slightly higher ahead of the open. BP (BP) and plaintiffs involved in the legal battle over the Gulf of Mexico oil spill said Friday they have reached an agreement. BP estimated that it would have to pay about $7.8 billion in the Deepwater Horizon disaster settlement.
Apple (AAPL, Fortune 500) said in a post on its website that the tech company has "created or supported" some 514,000 jobs in the United States, either through direct employment, the "App economy" or other means.
Currencies and commodities: The dollar strengthened against the British pound and the euro, but fell versus the Japanese yen.
Oil for April delivery slipped 56 cents to $106.14 a barrel.
Gold futures for April delivery fell $12.10 to $1,698 an ounce.
Bonds: The price on the benchmark 10-year U.S. Treasury held steady, with the yield flat at 1.98%.
AUGUSTAFRIENDS 3 March 2012 SCAN RESULTS (link back)
DQ- expected to Report Financial Results on 03/05/2012
BPAX Charts Current Share Price: $.76 (Mar 3)
IGC great information on IGC
BPAX- BioSante’s Prostate Cancer Vaccine Resulted in Stable Disease in Over 50% of Patients in Newly Published Study
Date : 03/05/2012 @ 7:55AM
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced publication of results from a Phase I dose escalation clinical study that show its GVAX Prostate cancer vaccine in treating metastatic castration-resistant prostate cancer patients (mCRPC) in combination with ipilimumab (Ipi; Yervoy; BMS), resulted in 53 percent of patients achieving at least stable disease, with two patients showing clear regression of metastases. In addition, 23 percent of patients in the higher dose cohorts had confirmed partial PSA (prostate specific antigen) responses of greater than 50 percent from baseline.
The study, titled, “Combined Immunotherapy with Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Allogeneic Prostate Cancer Cells and Ipilimumab in Patients with Metastatic Castration-Resistant Prostate Cancer: a Phase 1 Dose Escalation Trial” was published in current issue of The Lancet Oncology (February 2012). The study combined fixed doses of GVAX Prostate in combination with escalating 0.1, 0.3, 1.0, 3.0 and 5.0 mg/kg doses of Ipi. The study enrolled 12 patients in three dose escalation cohorts and 16 patients in an expansion Ipi 3.0 mg/kg cohort. The reported duration of disease stabilization ranged from 3-27 months, and the median duration of PSA response was 12 months, (range 2-21 months). There were no serious adverse events in the lower dose Ipi cohorts and administration of immunotherapy was well tolerated and safe. The investigators concluded that, “Further research on the combined treatment of patients with mCRPC with vaccination and Ipilimumab is warranted.”
The 28 patient Phase I study was conducted by researchers at the VU University Medical Centre in Amsterdam, Netherlands. BioSante’s Prostate cancer vaccine is made from allogeneic prostate cancer cells genetically altered to produce an immune system stimulator called GM-CSF, and irradiated to prevent cell growth. A Phase II GVAX Prostate clinical trial is anticipated to begin in 2012 at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
“We are very excited by the positive results of this prostate cancer study notably combined with recently reported excellent results in pancreatic cancer. This is encouraging news concerning the potential for GVAX cancer vaccines, especially when combined with other anticancer immunotherapies like Ipi, for treatment of a disease that can be so devastating for so many patients,” said Stephen M. Simes, BioSante’s president & chief executive officer.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development. BioSante also is developing a portfolio of cancer vaccines, with 17 Phase I and Phase II clinical trials currently on-going. Four of these vaccines have been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA). BioSante’s other products include a testosterone gel for male hypogonadism, for which a New Drug Application (NDA) was approved by the FDA on February 14, 2012, which is licensed to Teva Pharmaceuticals USA, Inc., and the Pill-Plus™, an oral contraceptive in Phase II clinical development by Pantarhei Bioscience B.V. BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Jazz Pharmaceuticals, BioSante's licensee. Additional information is available online at: www.biosantepharma.com.
VRNG Charts Current Share Price: $1.72 (Mar 3)
ZGNX Zogenix, Inc. Earnings Conference Call (Q4 2011)
Scheduled to start Thu, Mar 8, 2012, 4:30 pm Eastern
ZGNX charts - The recent low volume drop in the stock price to the 2.30 range (from $3.00) provides a compelling buying opportunity before ZGNX's financial results are announced after hours on Thursday, March 8. I believe this post earnings, new wave of buying interest could in short order easily take the stock up 25-30% from its current levels. But, this would only be the start of a rise back toward the 52-week high of $6.61.
Important to note is the 52-week high of $6.61 on March 10,2011, resulted from a 59%, five day gain in share price from the $4.16 price on the day that ZGNX released its annual results on March 3, 2011. This stock can jump very fast on good news because of its tiny float.
If history is a guide, when Zogenix reports this week-- with much greater results than March 2011 attracting even greater investor demand-- ZGNX will be well on its way back to that $6.61 high
ZGNX Charts Current Share Price: $2.31 (Mar 3)
PZG News & Charts Paramount Gold and Silver earlier reported gold grades up to 27.1 g/T from bulk-minable San Francisco deposit in Mexico (PZG) 2.47 : Co reported that new drilling has found higher gold grades at the San Francisco target on its 100%-owned San Miguel Project in Mexico. Eight new holes in the northern and western portions of the San Francisco deposit have returned higher-grade mineralization up to 27.1 g/T of gold and 24.0 g/T of silver, and near surface, wide intercepts including 23.6 meters grading 1.51 g/T of gold and 11.9 g/T of silver, confirming the bulk tonnage nature of this deposit. Drilling continues at the San Miguel Project with three core rigs.
PZG Charts Current Share Price: $2.47 (Mar 3)
ECYT News & Charts - Endocyte to resume patient enrollment in Proceed Phase 3 trial in the U.S. (ECYT) 3.49 : Co announced that the FDA has approved the importation of Endocyte's supply of Doxil from Europe into the U.S. for use in the PROCEED Phase 3 trial. The trial was initiated in May 2011 but enrollment stopped later in the year due to global shortages of Doxil. Endocyte plans to provide additional updates on clinical development plans as part of the fourth quarter earnings announcement and conference call in mid-March.
ECYT Charts Current Share Price: $3.49 (Mar 3)
NWY Charts Current Share Price: $2.84 (Mar 3)
Good Morning GR8 -- got it Thanks!
Jones Soda Co. Thursday, March 8, 2012 at 4:30 p.m. (NASDAQ: JSDA - News), a leader in the premium soda category and known for its unique branding and innovative marketing, today announced that it will host a conference call to discuss financial results for its fourth quarter and fiscal year ended December 31, 2011 on Thursday, March 8, 2012 at 4:30 p.m. Eastern Time. Jones Soda will announce its financial results for this period in a press release after the market close on March 8, 2012.
Good Morning Ecostate
ZGNX SA article just out. Gonna be a nice day.
http://seekingalpha.com/article/411001-zogenix-smart-biotech-buy-before-earnings
Please delete post AF...SPAH is a pinky
IGC wanna get a slice of the big indian boom cake ...before hedgies get em all
ironman mission accomplished:
http://www.indiaglobalcap.com/igc020712.pdf
http://www.hfironman.net/en/
http://topics.nytimes.com/topics/news/business/companies/india-globalization-capital-inc/index.html
what was it about?
http://www.reuters.com/finance/stocks/IGC/key-developments/article/2416772
Bro, those are not buys. Those are shares sold. I wonder why VP, Gen. Counsel & Secy of PEIX would sell shares at around 1.23.
I'm expecting a good week from HTM
IGC runner this week imo
Followers
|
2543
|
Posters
|
|
Posts (Today)
|
182
|
Posts (Total)
|
658988
|
Created
|
06/03/08
|
Type
|
Free
|
Moderator AugustaFriends | |||
Assistants jobynimble JDUB Mark |
Sign up for Email Updates: http://investorshub.advfn.com/boards/chairmail_sub.asp?board_id=12753
Chart Lessons by IAMGEND - A must learn for all traders
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=76625096
Chart tools:
(1) I use http://www.stockcharts.com for charting
(2) For more info on chart formations, see http://www.chartpatterns.com
(3) Chart indicator definitions http://stockcharts.com/education/IndicatorAnalysis/
(4) Explore Level II here-http://www.hotstockmarket.com/forums/showthread.php?t=14938
(5) For a COMPLETE list of indicator meanings http://www.investopedia.com/categories/technicalanalysis.asp
(6) Top insider trades website: http://www.secform4.com/top-lists.htm
BOARD FOR IHUBS HOTTEST CHART PLAYS
http://investorshub.advfn.com/boards/board.aspx?board_id=18372
WHO'S HOT: http://investorshub.advfn.com/boards/hot_people.asp
CHART YOUR STOCKS HERE: http://stockcharts.com/index.html http://www.profitspi.com/
INSTANT TECHNICAL ANALYSIS: http://www.barchart.com/
NEWS FILTER: http://www.marketwatch.com/
GOOD READ: http://www.bloggingstocks.com/
ALL ABOUT TRADERS: http://www.tradersmagazine.com/
TRACK WHAT THE FUNDS ARE DOING - MY FAVORITE SITE!: http://www.mffais.com
COMMENTARY ON EVERYTHING STOCKS: http://www.istockanalyst.com/
BEST ONLINE BROKERAGE:http://www.nobletrading.com/index.php (ask for Efrain)
MARKET MAKERS: http://www.otcbb.com/dynamic/tradingdata/download/mmids.txt
SHORT DATA: http://shortsqueeze.com/
SEC FILINGS: http://www.sec.gov/edgar/searchedgar/companysearch.html
WALL STREET TABLOID: http://dealbreaker.com/
Posts Today
|
182
|
Posts (Total)
|
658988
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |